The global anti-epilepsy drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Patients who have seizures are given anti-epileptic medications. The rising number of drug approvals by regulatory bodies is expected to propel the global anti-epileptic drugs market over the forecast period. For instance, in November 2020, UCB, a global pharmaceutical company, received FDA approval for VIMPAT (lacosamide) CV as an adjunctive therapy in the treatment of primary generalised tonic-clonic seizures (PGTCS) in patients aged four years and older, as well as VIMPAT injection for intravenous use in children aged four years and older.
A full report of Wooden Decking Market is available at: https://orionmarketreports.com/global-anti-epilepsy-drugs-market/92808/
Looking towards the high demand for anti-epilepsy drugs key manufacturers of anti-epilepsy drugs are adopting several market growth strategies such as mergers & acquisitions, partnerships, and new product launches among others to meet the growing demand for anti-epilepsy drugs. For instance, in May 2021, The Epilepsy Foundation, a non-profit national foundation based in the United States, has partnered with Eisai Inc., a Japanese pharmaceutical company, to create the Epilepsy Digital Experience Navigator (EDEN), a platform designed to empower people with epilepsy, caregivers, and clinicians to use data to better understand and improve the epilepsy journey.
Furthermore, market key players are focusing on obtaining regulatory approvals, which is expected to drive the growth of the global anti-epileptic drugs market. For instance, Pfizer, Inc. announced in July 2019 that the US Food and Drug Administration had approved the first generic Lyrica (pregabalin) as adjunctive therapy for the treatment of partial-onset seizures in patients aged 17 and older.
Over the forecast period, the market is expected to grow due to an increase in the number of inorganic growth strategies such as partnerships by key players. For instance, in February 2019, SK Biopharmaceuticals and Arvelle Therapeutics agreed to collaborate on the development and commercialization of SK Biopharmaceuticals’ Cenobamate in Europe. Cenobamate is an anti-epileptic medication used to treat adults with partial-onset seizures.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Generation
- By Route of Administration
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Anti-Epilepsy Drugs Market Report by Segment
By Generation
- First Generation
- Second Generation
- Third Generation
By Route of Administration
- Oral
- Intravenous
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
